Edwards Lifesciences (EW) CVP reports tax-withholding share disposition

Rhea-AI Filing Summary

Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, reported a tax-related share disposition. On February 22, 2026, he transferred 432 shares of common stock at a price of $79.78 per share to cover tax withholding. After this transaction, he directly owns about 33,933.9103 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lippis Daniel J.

Role CVP, TAVR

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	432	$79.78	$34K

Holdings After Transaction: Common Stock — 33,933.91 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippis Daniel J.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, TAVR

3. Date of Earliest Transaction (Month/Day/Year)
02/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/22/2026		F		432	D	$79.78	33,933.9103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Edwards Lifesciences (EW) disclose for Daniel J. Lippis?

Edwards Lifesciences (EW) disclosed that executive Daniel J. Lippis reported a tax-withholding disposition of 432 shares. The shares were transferred to satisfy tax obligations rather than sold in the open market, reflecting routine administration of equity compensation.

How many Edwards Lifesciences (EW) shares were disposed of for taxes and at what price?

Daniel J. Lippis disposed of 432 Edwards Lifesciences (EW) common shares to cover taxes, at a reported price of $79.78 per share. This disposition was classified as a tax-withholding event under transaction code F, not a standard market sale.

What type of Form 4 transaction did Edwards Lifesciences (EW) report for Daniel J. Lippis?

The Form 4 for Edwards Lifesciences (EW) shows a non-derivative transaction coded F, a tax-withholding disposition. It represents payment of tax liability by delivering company shares rather than an open-market buy or sell initiated for investment purposes.

How many Edwards Lifesciences (EW) shares does Daniel J. Lippis hold after the reported transaction?

After the tax-withholding disposition, Daniel J. Lippis directly holds about 33,933.9103 Edwards Lifesciences (EW) common shares. This post-transaction balance reflects his remaining equity stake following the transfer of 432 shares to satisfy tax obligations.

Was the Edwards Lifesciences (EW) insider transaction a market sale or tax withholding?

The Edwards Lifesciences (EW) insider transaction was a tax-withholding disposition, not a typical market sale. Transaction code F indicates shares were delivered to pay tax liabilities associated with equity compensation, rather than sold on the open market for investment reasons.

Who is the insider involved in the Edwards Lifesciences (EW) Form 4 filing and what is his role?

The insider is Daniel J. Lippis, an officer of Edwards Lifesciences (EW) with the title CVP, TAVR. He reported a tax-withholding share disposition, reflecting routine handling of equity compensation-related tax obligations rather than discretionary trading activity.